Editas Medicine (EDIT) Misses Q1 EPS by 13c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St futures muted; Mideast talks, US-China summit in focus
- Activist Jana Partners calls for Six Flags sale - WSJ
- Oil holds near two-week lows while diesel cracks hit record peak
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
UPDATE: RBC Capital Starts Editas Medicine (EDIT) at Sector Perform
May 3, 2021 4:12 PM EDT(Updated - May 3, 2021 4:20 PM EDT)
RBC Capital analyst Luca Issi initiates coverage on Editas Medicine (NASDAQ: EDIT) with a Sector Perform rating and a price target of $40.00.
The analyst comments "EDIT has pioneered the field of gene editing... More
